View Older Stories View More Recent Stories

Oct 10, 2025 08:06PM Form 4 Adicet Bio, Inc. For: Oct 08 Filed by: ORBIMED ADVISORS LLC
Oct 10, 2025 07:56PM Form SCHEDULE 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 30, 2025 07:07PM Form SCHEDULE 13D/A MBX Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 12, 2025 05:09PM Form 4 PMV Pharmaceuticals, For: Sep 10 Filed by: ORBIMED ADVISORS LLC
Sep 10, 2025 06:51PM Form 144 PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Sep 2, 2025 09:53PM Form SCHEDULE 13D Shattuck Labs, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 2, 2025 09:52PM Form 4 Shattuck Labs, Inc. For: Aug 25 Filed by: ORBIMED ADVISORS LLC
Sep 2, 2025 09:49PM Form 3 Shattuck Labs, Inc. For: Aug 25 Filed by: ORBIMED ADVISORS LLC
Aug 29, 2025 03:48PM Form N-PX ORBIMED ADVISORS LLC For: Jun 30
Aug 26, 2025 06:30AM Shattuck Labs closes $103 million private placement, adds board members
Aug 15, 2025 05:28PM Form SCHEDULE 13D/A Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
Aug 14, 2025 06:07PM Form SCHEDULE 13G CytomX Therapeutics, Filed by: ORBIMED ADVISORS LLC
Aug 14, 2025 06:03PM Form SCHEDULE 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
Aug 14, 2025 06:00PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 14, 2025 05:56PM Form SCHEDULE 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 14, 2025 05:53PM Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
Aug 14, 2025 04:40PM Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
Aug 13, 2025 07:44PM Form SCHEDULE 13D/A ArriVent BioPharma, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 12, 2025 05:22PM Form 4 Turnstone Biologics Corp For: Aug 08 Filed by: ORBIMED ADVISORS LLC
Jul 30, 2025 09:30PM Form 4 ImageneBio, Inc. For: Jul 25 Filed by: ORBIMED ADVISORS LLC
Jul 30, 2025 09:28PM Form SCHEDULE 13D/A ImageneBio, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 24, 2025 05:45PM Form SCHEDULE 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 21, 2025 05:33PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 21, 2025 05:28PM Form SCHEDULE 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 15, 2025 08:18PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 9, 2025 08:06PM Form SCHEDULE 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 7, 2025 06:02PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 1, 2025 09:24PM Form 4 Corvus Pharmaceuticals, For: Jun 27 Filed by: ORBIMED ADVISORS LLC
Jun 26, 2025 05:10PM Form 4 Passage BIO, Inc. For: Jun 24 Filed by: ORBIMED ADVISORS LLC
Jun 24, 2025 06:49PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 18, 2025 08:23PM Form SCHEDULE 13D/A Ikena Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 17, 2025 05:30PM Form SCHEDULE 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 16, 2025 05:26PM Form 4 NeuroPace Inc For: May 14 Filed by: ORBIMED ADVISORS LLC
May 15, 2025 08:16PM Form SCHEDULE 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
May 15, 2025 08:13PM Form SCHEDULE 13G/A InspireMD, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2025 08:09PM Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2025 06:46PM Form SCHEDULE 13G Whitehawk Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 15, 2025 06:41PM Form SCHEDULE 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2025 04:19PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 14, 2025 08:49PM Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
May 12, 2025 07:13PM Form SCHEDULE 13D/A Edgewise Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 1, 2025 09:21PM Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Apr 25, 2025 07:48PM Form SCHEDULE 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 24, 2025 05:39PM Form 4 Passage BIO, Inc. For: Apr 24 Filed by: ORBIMED ADVISORS LLC
Apr 17, 2025 06:11PM Form 4 Passage BIO, Inc. For: Apr 15 Filed by: ORBIMED ADVISORS LLC
Apr 16, 2025 08:05AM Xtant Medical Holdings (XTNT) Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%
Apr 15, 2025 05:40PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 14, 2025 07:15PM Form 4 Xtant Medical Holdings, For: Apr 10 Filed by: ORBIMED ADVISORS LLC
Apr 14, 2025 07:10PM Form SCHEDULE 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
Apr 11, 2025 07:21PM Form SCHEDULE 13D/A Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
View More Recent Stories View Older Stories